A composite implant for sustained release of a therapeutic agent in an ocular area of a subject. The composite implant comprises a matrix of photopolymerized polymer formed from a photopolymerizable composition, a biodegradable polymer contained within the matrix, and a therapeutic agent dispersed or dissolved between the matrix and/or biodegradable polymer, wherein the implant is formed from an ocular composition comprising 99 to 60% (w/w) of the photopolymerizable composition. The composite implant can be used in methods of delivering a therapeutic agent to an ocular area in a subject in need thereof, particularly by injecting the implant into the ocular area. Methods of preparing the composite implant are also disclosed.

The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.

Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

The present invention relates to an active substance delivery system, preferably an anti-cancer agent delivery system, for use in the treatment of cancer in a human subject, comprising one or more anti-cancer agents and optionally further active substances, both included in nano- and/or microparticles, and a method for producing such a delivery system.

A denervation formulation including a denervation drug incorporated into a sustained-release matrix. The sustained-release matrix may include a polycarbonate and a fluoropolymer. The sustained-release matrix may form a plurality of particles to encapsulate the denervation drug. The denervation formulation may be delivered to a patients autonomic neural tissue, including but not limited to a renal sympathetic nerve, a carotid nerve, a pulmonary nerve, and/or a cardiac sympathetic nerve. Upon release, the denervation drug may ablate the patients autonomic neural tissue for treatment of cardiac disease, including but not limited to hypertension, heart failure, and/or atrial and ventricular tachycardia.

The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.

Procedures for targeted treatment of kidney fibrosis include administering to a subject in need of treatment of kidney fibrosis a compound including a plurality of nanoparticle including at least one BCL-2/BCL-xl inhibitor; at least one polymer comprising a member selected from the group consisting of PLGA, PEG or PVA; and at least one targeting peptide, wherein each of the plurality of nanoparticles defines a hollow shell formed by the polymer, the at least one BCL-2/BCL-xl inhibitor is located within an interior of the hollow shell, and the at least one targeting peptide is coupled to an exterior surface of the hollow shell.

A cerium oxide nanocomplex, a method for preparing the cerium oxide nanocomplex, a composition containing the cerium oxide nanocomplex as an active ingredient, and a method for preventing or treating inflammatory or autoimmune diseases. The composition may be used as an efficient nanoparticle therapeutic composition by applying a biocompatible dispersion stabilizer composed of an optimal combination to significantly improve the biomedical stability, biocompatibility, and efficiency of the production process of nanoparticles while maintaining the intrinsic pharmacological effect of the nanoparticles.

A novel therapeutic agent delivery system, methods of use and methods of formation thereof are presented. The novel delivery system is comprised of novel nanoparticles capable of at least partially encapsulating a therapeutic agent such as an anesthetic, antimicrobial, growth factor or protein. The nanoparticles are embedded with in a crosslinked hydrogel. The hydrogel can be administered directly to a patient or may be coated onto a device such as a catheter. The delivery system allows for a sustained release of the therapeutic agent over an extended period of time.